Breaking News
Investing Pro 0
Free Webinar - The Role of Psychology in Trading - Thursday, December 8, 2022 | 04:00PM EST Enroll Now

Search Results for "biomarin":

Results: 321

Quotes

BMRN Biomarin Pharmaceutical Inc Stock - NASDAQ equities AKBM Aker Biomarine AS Stock - Oslo equities B1MR34 Biomarin Pharmaceutical Inc Stock - BM&FBovespa equities BMRN Biomarin Pharmaceutical Inc Stock - Vienna equities AKBMNOK Aker Biomarine AS Stock - Stockholm equities
Show all (5)

News

MarketPulse: Roche's Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks
By Investing.com

Investing.com – Swiss-based Roche Holding's bumper offer to acquire Spark Therapeutics on Monday propped up the healthcare sector and fueled speculation on Wall Street that more merger activity...

U.S. stocks suffer fifth straight loss, even as Fed holds rates steady
By Investing.com

Investing.com -- U.S. stocks closed slightly lower on Wednesday, turning negative just before the close of trading, after the Federal Reserve held short-term interest rates steady at its June monetary...

U.S. stocks fall mildly, as Apple patent suit weighs on major indices
By Investing.com

Investing.com -- U.S. stocks fell mildly on Friday, as Apple Inc (NASDAQ:AAPL) weighed on all three major indices amid reports that some stores in Beijing stopped selling the iPhone 6, weeks ago,...

Show all (51)

Analysis

BioMarin Begins Pediatric Study On Achondroplasia Candidate
By Zacks Investment Research

BioMarin Pharmaceutical Inc (NASDAQ:CRSP) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks hereCRISPR Therapeutics’ loss per share...

BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%
By Zacks Investment Research

BioMarin Pharmaceutical Inc. (NASDAQ:EBS) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Is BMRN going up? Or down? Predict to see...

Biotech Stock To Watch: Sarepta, Biomarin, Acadia
By Joshua Rodriguez

Sarepta Therapeutics On Monday April 25, 2016 Sarepta Therapeutics (NASDAQ:SRPT) had a FDA advisory panel shoot down its drug Eteplirsen, used to treat patients with Duchenne Muscular Dystrophy --...

Show all (265)
Results: 5

Refine Results

Instrument Type

Region

 

Country

Exchange

Sector

 

Industry

 
Results: 51

Refine Results

Date

Date
 

Category

Provider

 

News

{{title}}
By {{provider}}

{{content}}

Please try another search

Results: 265

Refine Results

Date

Date
 

Category

Author

Analysis

{{title}}
By {{provider}}

{{content}}

Results: 0

Refine Results

Country

Importance

Economic Events

Results: 0

Tools & Sections

Results: 0

Authors

Continue with Google
or
Sign up with Email